Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer
Corcept Therapeutics Incorporated
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 8 of these applications claim priority to application 62/385,590, filed Sep 9, 2016. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Patent lifetimeUsedRemaining | Confidence |
|---|---|---|---|---|---|---|
| US 9,943,505 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence UsedRemaining | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 10,117,852 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 10,213,414 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 10,449,178 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 10,646,474 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 10,828,280 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 11,642,331 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| US 12,370,175 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer In force · High confidence | Corcept Therapeutics, Inc. | In force | High confidence | ||
| Application 19/242,707 | Glucocorticoid Receptor Modulators to Treat Pancreatic Cancer Pending Not granted | Corcept Therapeutics, Inc. | Pending | Not granted |
9 of 9 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
8 of these are in force and held by Corcept Therapeutics Incorporated.
Updated Nov 22, 2026 · includes USPTO assignment data published Nov 21, 2026, status data published Nov 22, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.